MetaCap

Fennec Pharmaceuticals (FENC) vs REGENXBIO (RGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fennec Pharmaceuticals (FENC) has outperformed REGENXBIO (RGNX) over the past year, gaining 66.1% versus a loss of 39.3%. Over five years, FENC leads with a +35.8% price change compared with -76.9% for RGNX. REGENXBIO is the larger company by market cap ($473.4 million vs $462.1 million), about 1.0 times the size.

Fennec Pharmaceuticals converts more of its revenue into profit, with a net margin of -21.8% versus -113.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FENC+66.12%RGNX-39.32%
+79%+10%-58%
Nov 21, 20251 yearNov 20, 2026
FENC+33.23%RGNX-78.63%
+39%-25%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FENC versus RGNX key metrics
MetricFENCRGNX
Share price$13.09$7.16
Market cap$462.14M$473.44M
1-day change-2.68%-0.28%
YTD return+70.00%-50.28%
1-year return+66.12%-39.32%
5-year return+35.79%-76.87%
P/E ratio (TTM)436.33—
Forward P/E12.47—
EPS (TTM)$0.03$-3.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.64M$170.44M
Revenue growth (YoY)-6.09%+104.54%
Net income (latest FY)$-9.74M$-193.88M
Operating margin-14.07%-94.58%
Net margin-21.82%-113.75%
52-week high$13.85$16.19
52-week low$5.65$5.46
Distance from 52-week high-5.49%-55.78%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+34.45%+198.88%
Average volume220.87K1.39M
Shares outstanding35.31M66.12M
Employees35371
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FENC has outperformed RGNX by 105.4 percentage points over the past year.
  • Fennec Pharmaceuticals is more profitable, keeping -21.8 cents of every revenue dollar as net income versus -113.8 cents for REGENXBIO.
  • REGENXBIO grew revenue faster in its latest fiscal year (+104.54% vs -6.09%).

About Fennec Pharmaceuticals

FENC stock →

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

About REGENXBIO

RGNX stock →

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees

FENC vs RGNX FAQ

Which is bigger, Fennec Pharmaceuticals or REGENXBIO?

REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $462.14M for Fennec Pharmaceuticals (FENC).

Which stock has performed better over the past year, FENC or RGNX?

FENC returned +66.12% over the past 12 months, compared with -39.32% for RGNX (price return, excluding dividends). Past performance does not predict future results.

Are Fennec Pharmaceuticals and REGENXBIO in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons